PL366012A1 - Kompozycja i sposób oznaczania glikozydazy - Google Patents

Kompozycja i sposób oznaczania glikozydazy

Info

Publication number
PL366012A1
PL366012A1 PL01366012A PL36601201A PL366012A1 PL 366012 A1 PL366012 A1 PL 366012A1 PL 01366012 A PL01366012 A PL 01366012A PL 36601201 A PL36601201 A PL 36601201A PL 366012 A1 PL366012 A1 PL 366012A1
Authority
PL
Poland
Prior art keywords
glycosidase
determining
composition
determining glycosidase
Prior art date
Application number
PL01366012A
Other languages
English (en)
Inventor
Sivaram Pillarisetti
Uday Saxena
Dongyan Wang
Original Assignee
Reddy Us Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics, Inc. filed Critical Reddy Us Therapeutics, Inc.
Publication of PL366012A1 publication Critical patent/PL366012A1/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/924Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
PL01366012A 2000-09-15 2001-09-14 Kompozycja i sposób oznaczania glikozydazy PL366012A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23307500P 2000-09-15 2000-09-15

Publications (1)

Publication Number Publication Date
PL366012A1 true PL366012A1 (pl) 2005-01-24

Family

ID=22875789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366012A PL366012A1 (pl) 2000-09-15 2001-09-14 Kompozycja i sposób oznaczania glikozydazy

Country Status (10)

Country Link
US (1) US6656699B2 (pl)
EP (1) EP1356083A2 (pl)
JP (1) JP2004529606A (pl)
AU (1) AU2001294563A1 (pl)
CA (1) CA2426517A1 (pl)
IL (1) IL154904A0 (pl)
MX (1) MXPA03002243A (pl)
NO (1) NO20031177L (pl)
PL (1) PL366012A1 (pl)
WO (1) WO2002023197A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366012A1 (pl) * 2000-09-15 2005-01-24 Reddy Us Therapeutics, Inc. Kompozycja i sposób oznaczania glikozydazy
EP1385990A4 (en) * 2001-05-09 2004-09-22 Insight Biopharmaceuticals Ltd METHODS AND MATERIALS USING HEPARANASE AS A DIAGNOSTIC MARKER FOR HEMOSTATIC DISORDERS
WO2003011119A2 (en) * 2001-07-31 2003-02-13 Reddy Us Therapeutics, Inc. Methods and compositions for diagnosis and treatment of vascular conditions
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2009075774A2 (en) * 2007-12-05 2009-06-18 Massachusetts Institute Of Technology Glycosaminoglycan-coated particles and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859581A (en) 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
EP0532695A1 (en) * 1990-05-31 1993-03-24 Board Of Regents, The University Of Texas System Immunochemical localization of heparanase in mouse and human melanomas
AU7368994A (en) * 1993-07-29 1995-02-28 Upjohn Company, The Use of heparanase to identify and isolate anti-heparanase compound
TW565614B (en) 1996-07-18 2003-12-11 Univ Australian Detection of mammalian heparanase activity and purification of mammalian heparanase
US5968822A (en) 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6190875B1 (en) 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
EP1032656A4 (en) 1997-10-28 2002-10-29 Univ Australian ISOLATED NUCLEIC ACID MOLECULES, WHICH CODES FOR ENDOGLUCURONIDASE FROM MAMMALS, AND THEIR USE
GB9802725D0 (en) 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds
EP1060252A2 (en) 1998-02-24 2000-12-20 PHARMACIA & UPJOHN COMPANY Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
EP1157118A4 (en) 1999-03-01 2002-07-17 Insight Strategy & Marketing POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS
GB9913415D0 (en) 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
PL366012A1 (pl) * 2000-09-15 2005-01-24 Reddy Us Therapeutics, Inc. Kompozycja i sposób oznaczania glikozydazy

Also Published As

Publication number Publication date
WO2002023197A3 (en) 2003-07-24
JP2004529606A (ja) 2004-09-30
WO2002023197A2 (en) 2002-03-21
MXPA03002243A (es) 2004-12-03
US6656699B2 (en) 2003-12-02
IL154904A0 (en) 2003-10-31
NO20031177D0 (no) 2003-03-14
US20020064806A1 (en) 2002-05-30
NO20031177L (no) 2003-05-14
CA2426517A1 (en) 2002-03-21
AU2001294563A1 (en) 2002-03-26
EP1356083A2 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
NO20022334L (no) Ny sammensetning og anvendelse
DK1339292T3 (da) Sammensætning og fremgangsmåde
ID29021A (id) Komposisi galantamina pelepasan terkontrol
DE60132732D1 (de) Primerzusammensetzung und Verbindungsverfahren
DE60020100D1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
EP1248642A4 (en) PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
PT945132E (pt) Composicao de ibuprofeno
NO20013393D0 (no) Brönnsementeringsfremgangsmåter og sammensetninger
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
ID30590A (id) Celana sekali pakai jenis-celana pendek
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
DE60231927D1 (de) Reibungsreduzierende Zusammensetzung und zugehöriges Verfahren
DK1112003T3 (da) Ny sammensætning og anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
EP1423399A4 (en) HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATIZING AGENTS
DE60106968D1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
FI981506L (fi) Elastomeerikompositio ja sen valmistusmenetelmä
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
FI990234L (fi) MenetelmäKIinnirullauksessa
PL366012A1 (pl) Kompozycja i sposób oznaczania glikozydazy
DK1061955T3 (da) Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
ATE418339T1 (de) Zusammensetzung und verfahren
FI20001716L (fi) Rankajõrjestely ja siihen liittyvõt menetelmõt